Pet Monoclonal Antibodies Market Size & Share 2024 – 2032

Pet Monoclonal Antibodies Market Size

Pet Monoclonal Antibodies Market size was valued at USD 967.3 million in 2023 and is estimated to grow at 14.2% CAGR from 2024 to 2032. The market has experienced significant expansion owing to the rising incidence of chronic diseases and increased research endeavors focused on developing new targeted therapies to address global animal healthcare needs. Conditions such as osteoarthritis, ligament injuries, and other age-related disorders are becoming more common in both companion and livestock animals.

For instance, according to the Companion Animal Health publications, osteoarthritis accounts for at least 80% of lameness and joint disease cases in companion animals. While osteoarthritis is often linked with older animals, a recent study on its prevalence and clinical signs in young dogs (aged 8 months to 4 years) revealed that 39.8% of these animals exhibited radiographic signs of osteoarthritis in at least one joint. This highlighted the growing need for effective treatment expanding the market demand. Moreover, growing awareness among pet owners for advanced and targeted therapies continues to drive the development and adoption of pet monoclonal antibodies in the coming years.
 

Pet monoclonal antibodies are specialized proteins produced in laboratories, designed to bind to specific targets in companion animals. They mimic the immune system's ability to recognize and neutralize pathogens or abnormal cells, making them potent tools for diagnosing and treating diseases. These antibodies are engineered to be highly specific, minimizing side effects and maximizing therapeutic efficacy. They are used across various companion animal healthcare applications, including treating infectious diseases, managing immune disorders, and combating cancer.
 

Pet Monoclonal Antibodies Market Trends

Advancements in monoclonal antibodies propel market growth by facilitating precise therapies that effectively combat diseases such as cancer, infectious diseases, and immune disorders. Continuous research and technological advancements support veterinary professionals in utilizing these targeted treatments, thereby increasing demand throughout the global animal healthcare sector.
 

• For instance, in July 2023, Invetx's development of species-specific, half-life extension technology for dogs and cats represented a significant advancement in pet monoclonal antibodies. This innovation confirmed the superior efficacy and prolonged activity of their therapies, enhancing treatment outcomes for chronic and serious diseases in pets. This patented technology underscored advancement in optimizing antibody drug treatments, potentially setting new standards in veterinary care.
   
• As a result, veterinarians and pet owners may increasingly favour these advanced therapies for their efficacy and extended duration, thereby driving demand in the pet monoclonal antibodies market globally.
   

Furthermore, the growing animal healthcare expenditure, growing government support, and strategic expansions by major players further propel the market demand.
 

Pet Monoclonal Antibodies Market Analysis

Based on animal, the market is categorized as dogs and cats. The dogs segment is set to lead the market, accounting for the largest revenue of USD 715.9 million in 2023, anticipating its dominance throughout the forecast period with a CAGR of 14.1%.
 

• The dogs segment dominated the market due to the high prevalence of chronic and infectious diseases among dogs, necessitating advanced treatments.
   
• The pet owners' increasing willingness to invest in the health and well-being of their dogs, coupled with the availability of targeted monoclonal antibody therapies, has significantly driven this market segment.
   
• Additionally, the growing number of pet dogs and the rising trend of pet humanization have further fueled the demand for effective and specialized treatments, consolidating the dominance of the dogs segment in the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application the pet monoclonal antibodies market is classified into dermatology, osteoarthritis, cancer, and other applications. The dermatology segment holds the largest market share of 48.9% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The dermatology segment dominance was asserted due to the high prevalence of skin conditions and allergies among pets. For instance, a study published in the Veterinary Sciences Journal in July 2022 found that atopic dermatitis (AD) is one of the most common pet allergies. In dogs, the prevalence of AD has increased due to greater exposure to indoor environments and processed pet foods. Consequently, the growing burden of AD among dogs spurred the demand for veterinary dermatology drugs, thereby fueling the growth of monoclonal antibodies anticipating opportunities in the market.
   
• In addition, the growing awareness among pet owners about the importance of treating dermatological issues, combined with the effectiveness of monoclonal antibodies in providing targeted and long-lasting relief, has driven this segment's growth.
   
• Thus, the aforementioned factors are expected to supplement the segmental growth.
   

Based on the end-user, the pet monoclonal antibodies market is segmented into veterinary hospitals, veterinary clinics, and academics and research institutes. The veterinary hospitals segment dominated the market with the highest share in 2023.
 

• Veterinary hospitals dominance was asserted by their comprehensive range of services and advanced medical facilities, which attract pet owners seeking high-quality care for their animals.
   
• These hospitals are equipped with specialized diagnostic and treatment capabilities, including the administration of monoclonal antibody therapies.
   
• The expertise of veterinary professionals and the availability of cutting-edge treatments in these hospitals make them the preferred choice for managing complex and chronic conditions in pets.
   
• As a result, the veterinary hospital's segment has seen significant growth and has become a leading segment in the market.
   

The U.S. dominated the North American pet monoclonal antibodies market accounting for USD 432.9 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The country’s prominence was attributed by high pet ownership rates, and significant investment in R&D. Also, high veterinary healthcare spending in the U.S. tends to further expand the market.
   
• For instance, according to the American Pet Products Association, in 2022, pet owners spent USD 31.5 billion on supplies, live animals, and medicine, and USD 35.9 billion on veterinary care and products. Thus, the increasing expenditure on veterinary care is driving the demand for effective treatment options, thereby propelling market growth.
   
• Additionally, strong support from regulatory bodies such as the FDA for clinical trials and product approvals further bolsters the U.S. market's growth and innovation.
   

Germany exhibited a high growth potential in the European pet monoclonal antibodies market.
 

• Germany is a key player in the market in Europe, known for its advanced veterinary care and stringent regulatory standards.
   
• The country's emphasis on research and technological innovation in veterinary sciences supports the development and adoption of targeted therapies for the treatments.
   
• In addition, growing awareness among pet owners about advanced therapies and the presence of leading veterinary research institutions and biotechnology companies contribute to Germany's significant role in the market.
   

The Asia Pacific pet monoclonal antibodies market is poised for rapid growth with a CAGR of 14.8% during the forecast period.

• The Asia Pacific market is poised for rapid growth due to increasing pet ownership, rising awareness about advanced veterinary treatments, and growing animal healthcare expenditure.
   
• Growing investment in veterinary healthcare is driving research for targeted therapies. Also, advancements in biotechnology and a growing focus on animal health are propelling the adoption of innovative treatments.
   

Pet Monoclonal Antibodies Market Share

The market is characterized by numerous established players striving to capitalize on the growing demand for advanced pet healthcare solutions. Key players are dominating the market with their diverse portfolio of monoclonal antibodies and strong distribution networks. Also, collaborations between academic institutions and industry players for R&D further intensify competition. Furthermore, emerging startups are also making significant strides, leveraging innovative technologies and strategic partnerships to gain traction in this evolving market landscape
 

Pet Monoclonal Antibodies Market Companies

Few of the prominent players operating in the pet monoclonal antibodies industry providing commercial and pipeline products are:

• Ceva Santé Animale
• Boehringer Ingelheim International GmbH
• Elanco Animal Health
• Merck Animal Health
• Sanofi
• Vetigenics
• Zoetis Inc.
   

Pet Monoclonal Antibodies Industry News:

• In October 2023, Merck Animal Health launched its caninized monoclonal antibody, Gilvetmab, to veterinary specialists practicing oncology across the U.S. Gilvetmab, is approved for the treatment of dogs with mast cell tumors and melanoma, aimed to expand the product offering in veterinary oncology. This launch underscored the expanding application of monoclonal antibodies in treating cancer in dogs, providing veterinary specialists with advanced therapeutic options.
   
• In May 2023, Elanco Animal Health Inc. received a conditional license from the U.S. Department of Agriculture (USDA) for the first Canine Parvovirus Monoclonal Antibody, proven to treat canine parvovirus. This product approval marked a significant advancement in the application of monoclonal antibodies in animals, highlighting the potential for these targeted therapies.
   

The pet monoclonal antibodies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Animal

• Dogs
• Cats

Market, By Application

• Dermatology
• Osteoarthritis
• Cancer
• Other applications

Market, By End-user

• Veterinary hospitals
• Veterinary clinics
• Academics and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa